One of the recent studies investigating the role of GLP-1 RA in HF was the STEP-HFpEF Trial in which 529 HFpEF patients with obesity were randomly assigned to receive either a GLP-1 RA (semaglutide) or placebo for 52 weeks [14]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.